Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$10.79
+1.2%		$12.94
$6.62
▼
$15.35
$1.04B1.35746,157 shs820,035 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-3.8%		$3.86
$2.23
▼
$6.51
$1.22B1.095.30 million shs4.61 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.56
-1.2%		$3.39
$2.51
▼
$5.45
$281.04M0.52.53 million shs1.82 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.69
+3.5%		$22.10
$6.50
▼
$39.49
$1.11B1.781.07 million shs773,269 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-3.09%-3.53%-24.88%-23.42%+28.90%
MannKind Corporation stock logo
MNKD
MannKind
+1.28%+20.06%-0.75%-12.61%-26.58%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-1.52%-3.72%-30.56%-32.55%-18.04%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-5.35%-2.06%-20.23%-12.29%-54.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$10.79
+1.2%		$12.94
$6.62
▼
$15.35
$1.04B1.35746,157 shs820,035 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-3.8%		$3.86
$2.23
▼
$6.51
$1.22B1.095.30 million shs4.61 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.56
-1.2%		$3.39
$2.51
▼
$5.45
$281.04M0.52.53 million shs1.82 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.69
+3.5%		$22.10
$6.50
▼
$39.49
$1.11B1.781.07 million shs773,269 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-3.09%-3.53%-24.88%-23.42%+28.90%
MannKind Corporation stock logo
MNKD
MannKind
+1.28%+20.06%-0.75%-12.61%-26.58%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-1.52%-3.72%-30.56%-32.55%-18.04%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-5.35%-2.06%-20.23%-12.29%-54.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.78
Moderate Buy$24.71128.20% Upside
MannKind Corporation stock logo
MNKD
MannKind
2.50
Moderate Buy$8.34124.60% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.36
Hold$8.63240.24% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90
Moderate Buy$41.71127.02% Upside

Current Analyst Ratings Breakdown

Latest RCKT, VOR, MNKD, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
9/22/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Hold (C)
9/16/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$15.00
9/16/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
9/15/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
9/11/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/11/2026
MannKind Corporation stock logo
MNKD
MannKind
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$8.00
9/3/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
9/1/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$11.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M12.78N/AN/A($0.07) per share-154.71
MannKind Corporation stock logo
MNKD
MannKind
$348.97M3.42$0.06 per share63.03($0.17) per share-21.85
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$2.56 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7115.25N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.13N/AN/AN/A-11.08%N/A-6.31%11/4/2026 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$223.12M-$0.17N/AN/AN/AN/A-52.77%-44.92%11/5/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest RCKT, VOR, MNKD, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/10/2026Q2 2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$0.86$1.08+$0.22$1.08$0.22 millionN/A
8/5/2026Q2 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.0075-$0.01-$0.0025-$0.06$108.08 million$109.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.72
1.41
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.24
9.24
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
21.30%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
39396.04 million88.94 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
592321.54 million313.18 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
202109.78 million86.39 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened
September 30 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-jumps-53-heres-what-happened-2026-09-30/
Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 7:33 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69706309-vor-biopharma-telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis-399.htm
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 12:59 PM  |  marketscreener.comM
Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes
September 29 at 12:59 PM  |  boursorama.comB
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370807/0/en/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis.html
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
September 29 at 7:59 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VOR/pressreleases/4850802/vor-biopharma-vor-gets-a-buy-from-stifel-nicolaus/
Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056562
Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-stock-has-average-price-target-of-4171-according-to-brokerages-2026-09-28/
【VOR】Vor Biopharma
September 23, 2026  |  note.comN
Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia
September 23, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/vor-biopharma-no-forum-stifel-2026-telitacicept-aposta-em-dupla-estrategia-93CH-2073344
Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局
September 23, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3580464
Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/vor-biopharma-al-forum-stifel-2026-telitacicept-punta-su-doppia-strategia-93CH-3560029
Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía
September 23, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/vor-biopharma-en-foro-stifel-2026-telitacicept-avanza-en-doble-via-93CH-3774116
Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-shares-down-82-should-you-sell-2026-09-23/
Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-trading-up-61-still-a-buy-2026-09-22/
Vor Biopharma: A Funded Replication Story With Franchise Potential
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947759-vor-biopharma-a-funded-replication-story-with-franchise-potential
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VOR/latest-news/
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Split image showing a GameStop store checkout counter beside a laptop displaying the eBay website, with a graded Pokémon card nearby.
GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
By Thomas Hughes | September 10, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
A hard disk drive stands upright on a server rack in a data center aisle lined with illuminated equipment.
5 Buy-and-Hold Stocks Built to Weather a Volatile Market
By Chris Markoch | September 16, 2026
A fighter jet with open engine panels sits on an aircraft carrier deck at sunset, with the ship's superstructure visible in the background.
Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
By Jeffrey Neal Johnson | September 4, 2026
MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$10.79 +0.13 (+1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$10.84 +0.05 (+0.46%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.80 -0.15 (-3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$3.82 +0.02 (+0.50%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$2.56 -0.03 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$2.64 +0.08 (+3.09%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$18.69 +0.63 (+3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$18.78 +0.09 (+0.46%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas